JPS5978121A - Preparation of substance for hyperfunctioning phagocytic cell and product - Google Patents

Preparation of substance for hyperfunctioning phagocytic cell and product

Info

Publication number
JPS5978121A
JPS5978121A JP57189624A JP18962482A JPS5978121A JP S5978121 A JPS5978121 A JP S5978121A JP 57189624 A JP57189624 A JP 57189624A JP 18962482 A JP18962482 A JP 18962482A JP S5978121 A JPS5978121 A JP S5978121A
Authority
JP
Japan
Prior art keywords
substance
freeze
bands
dialyzed
hyperfunctioning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP57189624A
Other languages
Japanese (ja)
Inventor
Takao Shinoda
近沢信元
Akira Yagi
信太隆夫
Hiroshi Nishimura
西村浩
Itsuo Nishioka
西岡五夫
Kiwaji Oota
太田喜和二
Nobumoto Chikasawa
八木晟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maruho Co Ltd
Original Assignee
Maruho Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruho Co Ltd filed Critical Maruho Co Ltd
Priority to JP57189624A priority Critical patent/JPS5978121A/en
Publication of JPS5978121A publication Critical patent/JPS5978121A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

NEW MATERIAL:A substance hyperfunctioning phagocytic cells Aa-50 having the following properties; [alpha]<20>D:-57.1 deg. (c=0.5, 0.3M NaCl). Constituent amino acids: Asp, Thr, Ser, Glu, Pro, Gly, Ala, Val, Ile, Leu, Try, Phe, Lys, His and Arg; Elementary analysis: C, 45.53%; H, 6.35%; N, 5.22%. Disk polyacrylamide gel electrophoresis (9.5pH, 7% gel): five bands. Disk sodium dodecyl sulfate (SDS)- polyacrylamide gel electrophoresis (7.2pH, 10% gel): five bands. USE:Substances hyperfunctioning phagocytic cells. PROCESS:A leaf of a wild aloe in the growth or flowering period is stored for a given number of days in a cold dark place, and then ground and centrifuged to give a supernatant liquid, which is freeze-dried, dialyzed and fully desalted to give an internal liquid (undialyzed part). The resultant internal liquid is then freeze-dried to afford the aimed yellowish white powder Aa-50.

Description

【発明の詳細な説明】 本発明はアロエ葉より得られる新しい喰菌細胞機能冗進
作用を有する物質Aa−so及びその製法に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a new substance Aa-so obtained from aloe leaves that has the effect of enhancing bacterial cell function and a method for producing the same.

アロエは古来万能薬として珍重される代表的f、r 民
間薬である。このアロエはユリ科アロエ属植物の中、例
えばキグチアロX (Aioe arborescen
sMilL var、 natalensis Ber
ger) 、  ノコ]゛う70工(A perryi
 Baker)、キュラソウy O工IAbarbad
ensis Miller)、ケープアロエ(A、、、
、、f e r o、xMiller又はこれとA a
fricans Miller及びAspicata 
Bakerとの交雑種)などを総称する語であるか、と
りわけ、ソコトラアロエは既に西暦紀元前400年にギ
リシャ人によりその存在が知られ、アレキサンダー大王
はギリンヤ人を東アフリカ沖のソコ]・う(Sokot
ra)島に派遣し、その栽培及び保存に尽力させたと記
録されている。
Aloe is a typical folk medicine that has been prized as a panacea since ancient times. This aloe is a plant of the genus Aloe of the family Liliaceae, such as Aioe arborescen
sMIL var, natalensis Ber
ger), Noko] U70 (A perryi)
Baker), Curacao YO Engineering IA Barbad
ensis Miller), Cape Aloe (A.
,, f e r o, xMiller or this and A a
fricans Miller and Aspicata
The existence of the Socotra aloe was already known by the Greeks in 400 B.C.E., and Alexander the Great led the Girinyan people to the Sokotra Aloe off the coast of East Africa.
ra) It is recorded that he was dispatched to the island and made efforts to cultivate and preserve it.

従って、このアロエの成分については従来から多くの薬
学者の注目が集まり、例えばキダチアロエからは下剤成
分(バルバロイやン)、抗腫i成分(アロエマノナノ及
びアロエミノン)、抗炎症成分(アロエウルシノ)、腫
瘍細胞凝集活性物質(アロクチンA)及び赤血球凝集活
性物質(アロクチノB)などの諸成分が単離されている
Therefore, the components of aloe have been attracting the attention of many pharmacologists for a long time. Various components such as an agglutinating active substance (alloctin A) and a hemagglutinating active substance (allottin B) have been isolated.

本発明者らは過去の研究とは別個の観点からヒト(成人
気管支喘息(慢性及び経度)患者)の末梢血白血球の貧
食能(phagocytosis)を指標としてアロエ
の含有する感染防御作用物質を探索した結果、特に暗冷
所で保存したアロエの括潰物(シ、−ス)を遠心して得
た上清を透析して充分脱塩した内液(不透析部)中に貴
食能を亢進させる成分が含有される事実をつきとめ、該
透析内液を凍結乾燥して得られる帯黄白色の粉末をAa
−50と命名した。本物質は、電気泳動試験の結果から
少なくとも5種類の多糖類及びプロティン又はグリコプ
ロティンの混合物と推定され、以下の物理・化学的性状
を示す。
The present inventors explored the infection-preventing substance contained in aloe using the phagocytosis of peripheral blood leukocytes in humans (adult bronchial asthma (chronic and chronic) patients) as an indicator from a perspective different from past research. As a result, we found that the internal fluid (non-dialysed portion), which was thoroughly desalinated by dialyzing the supernatant obtained by centrifuging the crushed aloe vera powder stored in a dark place (sheath), enhanced the palatable activity. Aa
It was named -50. Based on the results of electrophoresis tests, this substance is estimated to be a mixture of at least five types of polysaccharides and proteins or glycoproteins, and exhibits the following physical and chemical properties.

I R(vKBr、 cm’−’) : ’3300.
1730.1650.’ 1540.1050ax UV(λ03MNaC’、 C=0.65)  280
nmax 旋光度〔α] %0=−57.1°(C=0.3MNa
(!’] )構成アミノ酸:アスパラギン酸、スレオニ
ン、セリン、グルタミン酸、プロリン、グリシノ、アラ
ニン、バリン、イノロインノ、ロイシン、チロシン、フ
1ニルアラニノ、リジン、ヒスチジン及ヒアルギニノ・ ディスク電気泳動 ポリアクリルアミドゲル(p149.5 、7%ゲル)
にて5本のバンド(発色剤゛クーマノジーブリリアン1
〜ブルー及びペリオテート・ジット(発色剤:クーマソ
シーブリリアノ1〜ブルー及びペリオデート・シンフ試
薬)。
I R (vKBr, cm'-'): '3300.
1730.1650. '1540.1050ax UV (λ03MNaC', C=0.65) 280
nmax Optical rotation [α] %0=-57.1° (C=0.3MNa
(!']) Constituent amino acids: aspartic acid, threonine, serine, glutamic acid, proline, glycino, alanine, valine, inoloinno, leucine, tyrosine, fluorinylalanino, lysine, histidine, and hyarginino disk electrophoresis polyacrylamide gel (p149. 5, 7% gel)
5 bands (coloring agent ``Coomanosie Brilliant 1'')
~ Blue and Periodate Dit (color former: Coomassie Brigliano 1 ~ Blue and Periodate Schimpf reagent).

因みに、本発明出願前公表された前掲アロクチンA及び
アロクチノBは、共に分子量約18000及び2400
0の糖タンパクである点てAa−50を構成する各成分
と類似するかに見えるが、後者は前2者の構成アミノ酸
であるレスティノを含有していないから、巨視的にも前
者と別異のものである。
Incidentally, alloctin A and alloctin B, which were published before the filing of the present invention, both have molecular weights of approximately 18,000 and 2,400.
Although it appears to be similar to each component of Aa-50 in that it is a glycoprotein of Aa-50, the latter does not contain restino, which is a constituent amino acid of the former two, so it is macroscopically different from the former. belongs to.

以下本発明の基礎となった実験事実につき記述する。The experimental facts that formed the basis of the present invention will be described below.

(3) 試料の調製 (1)  成長期又は開花期の自生アロエ葉を、一定の
日数、4℃〜30°Cの各温度で3〜10日間暗所に保
存後、磨砕し、110000rpで10分間遠心し、上
清を凍結乾燥する。次いてこれをセロファンチューブに
入れて2日間蒸溜水に対し透析し、透析部(外液)は4
5℃以下にて濃縮後、不透析部(内液)はそのまま夫々
凍結乾燥する。各サンプル(100mg)はp H7,
2の0.15MIJン酸塩緩衝液中5 mlに溶かし、
測定時倍数稀釈する。
(3) Preparation of samples (1) Wild aloe leaves in the growing or flowering stage were stored in the dark for a certain number of days at a temperature of 4°C to 30°C for 3 to 10 days, then ground and crushed at 110,000 rpm. Centrifuge for 10 minutes and lyophilize the supernatant. Next, this was placed in a cellophane tube and dialyzed against distilled water for 2 days, and the dialysis part (external solution) was
After concentration at 5° C. or lower, the non-dialyzed portion (internal solution) is freeze-dried as it is. Each sample (100 mg) had a pH of 7,
2 in 5 ml of 0.15 MIJ phosphate buffer,
Dilute multiple times when measuring.

(2)  成長期に採取した新鮮アロエ葉を、4°Cで
5日間暗所に又は15℃で5日間明所に保存後、注意し
て皮層とゼリー状パルプとに分離し、夫々について(1
)と同様に測定試料を作る。
(2) Fresh aloe leaves collected during the growth period were stored in the dark at 4°C for 5 days or in the light at 15°C for 5 days, and then carefully separated into the cortex and jelly-like pulp, and each was separated into ( 1
) Prepare the measurement sample in the same way.

FB)  測定試料の調製 成人喘息患者の静脈血サンプル20m1に4mlの千5
%のデキストランB(分子量1.7X105)及及び5
00単位のヘパリノを含む生理食塩水溶液を加え、50
分間室温下に放置して赤血球を沈澱させる。白血球に富
む上清を圧搾して集め、調和ハノクス氏液で2回洗浄し
て好中球の測定に用いる。即ち、ギムザ染色後、好中球
を計数し、一定容の調和ハノクス氏液中に2×107個
の好中球が1 ml中に悪性するように試料液を調製す
る。
FB) Preparation of measurement sample: Add 4 ml to 20 ml of venous blood sample from an adult asthmatic patient.
% Dextran B (molecular weight 1.7X105) and 5
Add a saline solution containing 00 units of heparino,
Leave at room temperature for a minute to precipitate red blood cells. The leukocyte-rich supernatant is collected by squeezing, washed twice with Harmonic Hanox's solution, and used for neutrophil measurement. That is, after Giemsa staining, neutrophils are counted, and a sample solution is prepared such that 2 x 10 7 neutrophils are malignant in 1 ml of a certain volume of harmonic Hannoch's solution.

(C)  喰菌作用の測定 アレクサンダーら(Alexander、 Windh
orst& Good、 、 Lab、 CI in、
 Med、 、 72.136−148(1968))
の方法に従い、1 ml当り2×107個の好中球と5
%の仔牛血清と0.05mA!のアロエサンプルを含む
試料液を作り、この試料液を37℃で7分間インキ・べ
−1・する。−万、酵母菌を生理食塩水1 mlにつき
25 X 107個の菌体を含むように稀め、100°
Cて30分間加熱する。この死滅酵母菌体懸洩液旧ml
に上記イノキュベート液0.1 rnlを加え、37°
Cで60分間イノキュベートシ、供試好中球の喰菌係数
を下式に従って求める。
(C) Measurement of glucocorticoid activity Alexander et al.
orst & Good, , Lab, CI in,
Med, 72.136-148 (1968))
According to the method of 2 x 107 neutrophils and 5
% calf serum and 0.05mA! Prepare a sample solution containing an aloe sample, and ink this sample solution at 37° C. for 7 minutes. - 10,000, dilute yeast to contain 25 x 107 cells per ml of physiological saline, and incubate at 100°
Heat at ℃ for 30 minutes. Old ml of this sterilized yeast cell suspension
Add 0.1 rnl of the above incubate solution to 37°
Incubate at C for 60 minutes, and determine the bactericidal coefficient of the test neutrophils according to the following formula.

ず対照ではアロエサンプルの代りに0.05.nlの0
.15Mリン酸塩緩衝液(pH7,2)を加える。
In the control, 0.05. 0 of nl
.. Add 15M phosphate buffer (pH 7.2).

FD+分析法 (1)  滲透圧:アロエサンプルの滲透圧はフリスク
O5滲透圧計(Friske As5ociates、
 Inc、 。
FD+ analysis method (1) Osmotic pressure: The osmotic pressure of the aloe sample was measured using a Friske O5 osmometer (Friske As5ociates).
Inc.

U、 S、 A)を用いて測定。Measured using U, S, A).

5mlのO,15Mリン酸塩緩衝液(pH7,2)に溶
かされた粗製試料100 myは325m05m/lを
示す(生理食塩水: 308 m05m/1 )。
100 my of the crude sample dissolved in 5 ml of O, 15M phosphate buffer (pH 7.2) shows 325 m05 m/l (saline: 308 m05 m/1).

(2)  物理的及び分光的分析:赤外スペクトルはK
OKEN DS−301分光計により、紫外スペクトル
はHitachi 200−10分光言4により測定。
(2) Physical and spectroscopic analysis: Infrared spectrum is K
Ultraviolet spectra were measured using an OKEN DS-301 spectrometer and a Hitachi 200-10 spectrometer 4.

旋光度はJASCODIP−4旋光計にて測定。アミノ
酸分析のため、試料を6N塩酸と共に真空封管中で20
時間110℃に加熱し、日立835アミノ酸分析計を用
い測定。ディスク電気泳動は、(i) I)H9,5で
7%のポリアクアリルアミドゲル及び(il) PH7
,2で10%の5DS−ポリアクリルアミドゲルを用い
て実施。
Optical rotation was measured using a JASCODIP-4 polarimeter. For amino acid analysis, samples were incubated with 6N hydrochloric acid in a vacuum sealed tube for 20 min.
Heated to 110°C for an hour and measured using a Hitachi 835 amino acid analyzer. Disk electrophoresis was performed on (i) I) 7% polyacrylamide gel in H9,5 and (il) PH7.
, 2 using a 10% 5DS-polyacrylamide gel.

発色剤:クーマフノーブリリアントプル 。Coloring agent: Coomaf No Brilliant Pur.

−及びペリオデート・シンフ試薬(ザノカリウス、ゼル
、モリノン及びウノドロンク(1969) )。
- and periodate Schimpf reagent (Zanocarius, Zell, Morinon, and Unodoronk (1969)).

(3)  クロマトグラフィー二不透析物lyを0.0
2MNH4HC0,30mZ ニ溶かし、DEAE−セ
#。
(3) Chromatography didialysate ly 0.0
Dissolve 2MNH4HC0.30mZ, DEAE-Se#.

ファイン(チノノ株式会社)500−を填めた4×25
cInのカラムに負荷し、カラムに0.02MNH,H
CO3液を20d/時の流速で流す。溶出液324rn
lを蒸溜水に対し透析した後凍結乾燥か すると、無色の軟、い物質30■が得られる。
4×25 filled with Fine (Chinono Co., Ltd.) 500-
Load the column with cIn and add 0.02M NH,H to the column.
The CO3 liquid is flowed at a flow rate of 20 d/h. Eluate 324rn
After dialysis against distilled water and freeze-drying, 30 ml of a colorless, soft, thick substance is obtained.

次いで、前記カラムを0.3MNaClで院流し、溶出
液234dを蒸溜水に対し透析後、凍結乾燥すると淡い
褐色粉末1100Inを得る。カラムからの溶出液は日
立分光光度計を用いそのまま280nmで、及びフ、ノ
ル硫酸法(デュボアら(1956) )により、490
nm  でモニター。
Next, the column was flushed with 0.3M NaCl, and the eluate 234d was dialyzed against distilled water and lyophilized to obtain 1100In as a pale brown powder. The eluate from the column was directly measured at 280 nm using a Hitachi spectrophotometer, and at 490 nm using the fluorinated norsulfuric acid method (Dubois et al. (1956)).
Monitor with nm.

+Ej  本発明物質の喰菌作用 (1)  成長期に収穫されたアロエエキスの効果下表
−1の示すとおり、5〜10日間、20°Cに暗所保存
された材料から得られたエキスが最大の効果を有する。
+Ej Bactericidal action of the substance of the present invention (1) Effects of aloe extract harvested during the growing season As shown in Table 1 below, the extract obtained from the material stored in the dark at 20°C for 5 to 10 days have the greatest effect.

3日間、25°Cに保存されたサンプルは一見最大の効
力を有するかに見えるが、恐らく実験誤差によるものて
あらう。
Samples stored at 25°C for 3 days appear to have the greatest potency, but this is likely due to experimental error.

表  −1 (2)  開花期に収穫されたアロエエキスの効果下表
−2に示される。各サンプルの喰菌作用への影響には上
表−1と同様の傾向が見られるが、喰菌係数は1.00
0より低く、むしろ正常の喰菌作用を阻害する傾向が見
られる。
Table 1 (2) Effects of aloe extract harvested during flowering period are shown in Table 2 below. The influence of each sample on the bactericidal action shows the same tendency as shown in Table 1 above, but the bactericidal coefficient is 1.00.
It is lower than 0, and rather tends to inhibit the normal bactericidal action.

表  −2 (3)  全英エキス、ゼリ一部ならひに全葉の透析部
及び不透析部の喰菌作用増強効果 サンプルは前述の(A) (1)の方法にて調製。
Table 2 (3) Whole British extract, jelly, or part of the whole hive leaf, has an effect on enhancing the glucocorticoid activity of the dialyzed and non-dialyzed parts Samples were prepared using the method described in (A) (1) above.

下表−3に示されるように、セリー状エキス及び全英の
透析部は喰菌作用に対し陽性の挙動を示した。参照とし
たバロルバイロノは、喰菌作用に対しネガチブの挙動を
示す。
As shown in Table 3 below, the celery-like extract and the whole British dialysis section showed positive behavior with respect to bacterial action. Valorbairono, which was used as a reference, exhibits negative behavior against bacterial action.

表  −3 (4)  全英、皮層又はゼリ一部からの透析部もしく
は不透析部の喰菌作用増強効果 サンプルは前A(2)の方法に従って調製。
Table 3 (4) Samples for the effect of enhancing the bacteriostatic activity of the dialyzed or non-dialyzed areas from the whole body, cortical layer, or part of the jelly were prepared according to the method described in A (2) above.

下表−4に示されるようにゼリ一部の不透析部に喰菌作
用増強効果が見られた。
As shown in Table 4 below, the effect of enhancing the bactericidal action was observed in some non-dialyzed parts of the jelly.

これに反し皮層部からの不透析部では逆に本効果の抑制
が認められた。
On the contrary, this effect was suppressed in the non-dialysis area from the cortical layer.

表  −4 (F)  本発明物質の物理・化学的性状1週間透析後
の不透析部(Aa−50)の物理・化学的性状は下達の
とおりニー 旋光度:〔α、:] 古0−s 7.1°(c=0.6
5 、0.3M NaCl )赤外吸収スペクトル(λ
KBrcm1):max ’ 3300(強、−0H)、1700(強、−COOH)
、1650(強。
Table 4 (F) Physical and chemical properties of the substance of the present invention The physical and chemical properties of the non-dialysed area (Aa-50) after one week of dialysis are as follows: Knee optical rotation: [α, :] Old 0- s 7.1° (c=0.6
5,0.3M NaCl) infrared absorption spectrum (λ
KBrcm1): max' 3300 (strong, -0H), 1700 (strong, -COOH)
, 1650 (strong.

−NH2) tOH 紫外部吸収スペクトル(ν  、 nm) ; 280
呈色反応:ローリー試薬及びフ、ノール硫酸により陽性
-NH2) tOH Ultraviolet absorption spectrum (ν, nm); 280
Color reaction: Positive with Lowry's reagent and phenol sulfuric acid.

元素分析: C; 45.53%、N;5.22%、H
;6.35%構成アミノ酸: ASp、 Thr、 S
er、 Glu、 Pro、 Gly。
Elemental analysis: C; 45.53%, N; 5.22%, H
;6.35% Constituent amino acids: ASp, Thr, S
er, Glu, Pro, Gly.

Ala、 Val、 T Ie、 Leu+ TYr、
 Phe、 Lys、 His、 Arg。
Ala, Val, T Ie, Leu+ TYr,
Phe, Lys, His, Arg.

ポリアクリルアミドゲル及び5DS−ポリアクリルアミ
ド、 ゲルディスク電気泳動: 5本のバンド(発色剤
としてクーマツノーブリリアントブルー及びペリオデー
ト・シッフ試薬のいづれを用いたときも同じ。) 以上の結果より本物質は多糖類及びプロティン又はグリ
コブロチイノの混合物である少なくとも5種類の単位成
分から構成されていることが推定される。なお、本不透
析物(Aa−50)の喰菌係数は1.312±0.10
6であった。
Polyacrylamide gel and 5DS-polyacrylamide, gel disk electrophoresis: 5 bands (same when using either Kuumatsunow Brilliant Blue or Periodate Schiff reagent as coloring agents). From the above results, this substance It is estimated that it is composed of at least five types of unit components that are a mixture of saccharides and proteins or glycobrothiino. The bactericidal coefficient of this non-dialysate (Aa-50) is 1.312±0.10.
It was 6.

(G)  本発明物質の薬理作用 4°Cで7日間暗所に保存されたアロエのエキスの精製
物(Aa−50)を各年令の患者に投与した結果を下表
−5に示す。表示の如<51才以上の患者では6285
%に有効であったが、より若年の患者を含めた平均では
333%に低下した。また、内因性患者では本エキスは
429%に有効であったが、外因性患者に対しては16
7%にしか有効でなかった。さらにステロイド投与群と
非投与群の対比において、アロエエキスが後者に対し4
0%以上有効であるにかかわらず、前者に対し無効であ
ることは、重要な知見であると同時に感染防御薬剤とし
てのアロエエキスの作用に興味ある問題を提供するもの
である。
(G) Pharmacological effect of the substance of the present invention A purified aloe extract (Aa-50) stored in the dark at 4°C for 7 days was administered to patients of various ages. The results are shown in Table 5 below. As shown in <6285 for patients over 51 years of age.
%, but this dropped to 333% on average when younger patients were included. In addition, this extract was effective in 429% of endogenous patients, but 16% in exogenous patients.
It was only effective in 7%. Furthermore, in comparing the steroid-administered group and the non-steroid-administered group, aloe extract
Although it is more than 0% effective, the fact that it is ineffective against the former is an important finding and at the same time presents an interesting problem regarding the action of aloe extract as an infection prevention agent.

表  −5 注)投与量及び投与法:生理食塩水で20%に稀めたア
ロエエキス液5 mlを6ケ月間1日2回づつ投与 特許出願人 マルホ株式会社 手続補正書 特許庁長官着膨 和犬 殿 ] 事件の表示 昭和57年 特 許  願第189624号2、発明の
名称 ′ 喰菌細胞機能光進物質の製法及び製品3、 
補正をする者 事件との関係  特許出願人 4、代理人 5、 補正命令の日付   昭和58年2月22日(発
送日)6、 補正により増加する発明の数   0(別
 紙) 「 するかに見えるが、恐らく実験誤差によるものてあらう
Table 5 Note) Dosage and administration method: Administer 5 ml of aloe extract diluted to 20% with physiological saline twice a day for 6 months.Patent applicant: Maruho Co., Ltd. Procedural amendment filed by the Commissioner of the Japan Patent Office [Mr. Wainu] Indication of the case 1989 Patent Application No. 189624 2, Title of the invention ``Production method and product of a substance that enhances the function of glucocorticoid cells 3,
Relationship with the case of the person making the amendment: Patent applicant 4, agent 5, date of amendment order: February 22, 1982 (shipment date) 6, number of inventions increased by amendment: 0 (attached) I can see it, but it's probably due to experimental error.

表   −1 (2)  開花期に収穫されたアロエエキスの効果下表
−2に示される。各サンプルの喰菌作用への影響には上
表−1と同様の傾向が見られるが、喰菌係数は1.00
0より低く、むしろ正常の喰菌作用を阻害する傾向が見
られる。
Table 1 (2) Effects of aloe extract harvested during flowering period are shown in Table 2 below. The influence of each sample on the bactericidal action shows the same tendency as shown in Table 1 above, but the bactericidal coefficient is 1.00.
It is lower than 0, and rather tends to inhibit the normal bactericidal action.

表  −2 (3)  全集エキス、ゼリ一部ならびに全集の透析部
及び不透析部の喰菌作用増強効果 サンプルは前述の(Al (1)の方法にて調製。
Table 2 (3) Samples of the complete extract, part of the jelly, and the bacteriostatic effect of the dialyzed and non-dialyzed parts of the complete collection were prepared using the method described in (Al (1)) above.

下表−3に示されるようにゼリー状エキス及び全集の透
析部は喰菌作用に対し陽性の挙動を示した。参照とした
バロルバイロンは、喰菌作用に対しネガチブの挙動を示
す。
As shown in Table 3 below, the jelly-like extract and the dialyzed portion of the complete collection showed positive behavior against the bacillus effect. Valorviron, which was used as a reference, exhibits negative behavior against the bacillus effect.

表  −3 (4)  全集、皮層又はゼリ一部からの透析部もしく
は不透析部の喰菌作用増強効果 サンプルは前A(2)の方法に従って調製。
Table 3 (4) Samples for enhancing the bacteriostatic activity of the dialyzed or non-dialyzed portions from the complete collection, cortical layer, or part of the jelly were prepared according to the method described in A (2) above.

下表−4に示されるようにゼリ一部の不透析部に喰菌作
用増強効果が見られた。
As shown in Table 4 below, the effect of enhancing the bactericidal action was observed in some non-dialyzed parts of the jelly.

これに反し皮層部からの不透析部では逆に本効果の抑制
が認められた。
On the contrary, this effect was suppressed in the non-dialysis area from the cortical layer.

表  −4 (F)  本発明物質の物理・化学的性状1週間透析後
の不透析部(Aa−50)の物理・化学的性状は下達の
とおりニー− 旋光度: Car、)50−s7.xo(cm0.65
 、0.3M NaC1)赤寿吸収スペクトル(2ゝ”
 、 cm−1) :3300(強、−0H)、170
0(強、−COOH)、1650(強。
Table 4 (F) Physical and chemical properties of the substance of the present invention The physical and chemical properties of the non-dialysed part (Aa-50) after one week of dialysis are as follows: Optical rotation: Car, )50-s7. xo(cm0.65
, 0.3M NaC1) Akatsuki absorption spectrum (2ゝ”
, cm-1): 3300 (strong, -0H), 170
0 (strong, -COOH), 1650 (strong.

−Nl2) 紫外部吸収スペクトル(V 畠W+ nm ) : 2
8002) り若年の患者を含めた平均では33.396に低下した
。また、内因性患者では本エキスは429%に有効であ
ったが、外因性患者に対しては16.7%にしか有効で
なかった。さらにステロイド投与群と非投与群の対比に
おいて、アロエエキスが後者に対し40%以上有効であ
るにかかわらず、前者に対し無効であることは、重要な
知見であると同時に感染防御薬剤としてのアロエエキス
の作用に興味ある問題を提供するものである。
-Nl2) Ultraviolet absorption spectrum (V Hatake W+ nm): 2
8002) The average number including younger patients decreased to 33.396. Additionally, this extract was effective in 429% of endogenous patients, but only 16.7% of exogenous patients. Furthermore, when comparing the steroid-administered group and the non-steroid-administered group, it is important to note that although aloe extract was more than 40% effective against the latter, it was ineffective against the former. This poses an interesting question regarding the action of extracts.

表  −5 (+4)           」Table-5 (+4)          

Claims (1)

【特許請求の範囲】 (1)  新鮮なアロエ葉の汁液を透析し、透析内液を
凍結乾燥することを特徴とする喰菌細胞機能冗進物質の
製法。 (2)  新鮮なアロエ葉の汁液が透析に先立ち遠心分
離された上清である特許請求の範囲第(1)項記載の製
法。 (3)  原料のアロエ葉が予め暗冷所で保存されたも
のである特許請求の範囲第(1)項又は第(2)項記載
の製法。 (4)  新鮮なアロエ葉の汁液を透析後、透析内液を
凍結乾燥して得られる帯黄白色の粉末であって、下記の
特徴を有する喰菌細胞機能冗進作用を有する物質(Aa
−50)。 KBr   −1゜ (i) I R(ν  、 cm  )  、 330
0.1730.1650゜ax 1540、1050 0.3MNaC1 (ii) U V (λ   、 cm0.65) :
 280nmax (hl) CαII)  −57,1°(cm0.5 
、0.3MNaCl )(1v)構成アミノ酸: As
p、 Thr、 Ser、 Glu、 Pro。 Gly、 Ala、 Val、 T IL Leu、 
Try、 Phe、 Lys。 His、Arg。 (v1元素分析値: 5本のバンド(発色剤、クーマツジ−ブリリア5本のバ
ンド(発色:クーマッンーブリリアントブルー及びペリ
オデート・シッフ試薬)
[Scope of Claims] (1) A method for producing a substance that enhances bacterial cell function, which comprises dialyzing the juice of fresh aloe leaves and freeze-drying the dialyzed solution. (2) The method according to claim (1), wherein the supernatant is obtained by centrifuging fresh aloe leaf juice prior to dialysis. (3) The manufacturing method according to claim (1) or (2), wherein the raw material aloe leaves are stored in a dark and cool place in advance. (4) A yellowish-white powder obtained by dialysis of fresh aloe leaf juice and freeze-drying the dialyzed fluid, which contains a substance (Aa
-50). KBr −1゜(i) IR(ν, cm), 330
0.1730.1650°ax 1540, 1050 0.3MNaC1 (ii) UV (λ, cm0.65):
280nmax (hl) CαII) -57,1° (cm0.5
, 0.3M NaCl) (1v) Constituent amino acid: As
p, Thr, Ser, Glu, Pro. Gly, Ala, Val, TIL Leu,
Try, Phe, Lys. His, Arg. (v1 elemental analysis value: 5 bands (coloring agent, 5 bands of Kumanzu Brilliant Blue and Periodate Schiff reagent)
JP57189624A 1982-10-27 1982-10-27 Preparation of substance for hyperfunctioning phagocytic cell and product Pending JPS5978121A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP57189624A JPS5978121A (en) 1982-10-27 1982-10-27 Preparation of substance for hyperfunctioning phagocytic cell and product

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57189624A JPS5978121A (en) 1982-10-27 1982-10-27 Preparation of substance for hyperfunctioning phagocytic cell and product

Publications (1)

Publication Number Publication Date
JPS5978121A true JPS5978121A (en) 1984-05-04

Family

ID=16244405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57189624A Pending JPS5978121A (en) 1982-10-27 1982-10-27 Preparation of substance for hyperfunctioning phagocytic cell and product

Country Status (1)

Country Link
JP (1) JPS5978121A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62286923A (en) * 1986-06-04 1987-12-12 Takao Shinoda Enhancer for poor appetite action
JPH0446128A (en) * 1990-06-13 1992-02-17 Yurika Kk Tablet product utilizing vacuum freeze-dried substance of plant belonging to genus aloe of family liliaceae and production thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62286923A (en) * 1986-06-04 1987-12-12 Takao Shinoda Enhancer for poor appetite action
JPH0446128A (en) * 1990-06-13 1992-02-17 Yurika Kk Tablet product utilizing vacuum freeze-dried substance of plant belonging to genus aloe of family liliaceae and production thereof
US6368624B1 (en) 1990-06-13 2002-04-09 Yurika Incorporated Tableted product prepared by vacuum freeze-drying of a plant belonging to genus aloe of family Liliaceae and the method for producing same
US6399095B1 (en) 1990-06-13 2002-06-04 Yurika Incorporated Tableted product prepared by vacuum freeze-drying of a plant belonging to genus aloe of family Liliaceae and the method for producing same

Similar Documents

Publication Publication Date Title
US8349377B2 (en) Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency
EP0759765B1 (en) Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
US9023810B2 (en) Use of a compound comprising D-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases
Takao Shida et al. Effect of Aloe extract on peripheral phagocytosis in adult bronchial asthma
JP3759162B2 (en) Bioactive products derived from peat, and pharmaceutical and cosmetic compositions containing the bioactive products
JPH11502514A (en) Shark cartilage extract, its production and use
JPS63222118A (en) anti-inflammatory composition
GB2052979A (en) Ophthalmological use for colostrum
JPH0987189A (en) Antiallergic agent containing isodon japonicus hara, paeonia suffruticosa andrews, perilla frutescens britton var. acuta kudo, and/or arunica montana linne
EP0101063B1 (en) Polypeptide acting on the immune system, process for isolating and purifying it, its use and composition containing it
EP0050636B1 (en) A polypeptide fraction for use as an antimicrobial drug
BR0215394B1 (en) Composition comprising aloe vera derivable polysaccharides, NAG-25 extract, ultrafiltered aloe extract, their preparation processes, their dosage forms, and their uses
JPH02149594A (en) Anti-inflammatory analgesic compound, its relating composition, their preparation and use
EP0531495A1 (en) Therapeutic and cosmetic compositions for treatment of skin.
DE3019847A1 (en) METHOD FOR PRODUCING HUMAN INTERFERON AND MEANS CONTAINING IT
JPS5978121A (en) Preparation of substance for hyperfunctioning phagocytic cell and product
US5151498A (en) Glycoprotein from avena sativa, process for its preparation, and pharmaceutical compositions containing same
US2666012A (en) Nose drops
JPH0959179A (en) Mouth hygienic agent effective for preventing cedar pollinosis
JP4224808B2 (en) Physiologically active substance
JPH06509060A (en) Therapeutic and cosmetic compositions for treating the skin
Cho et al. The Ameliorative Effect of Angelica acutiloba Ameliorates Through the NO/iNOS Pathway in Rats with Systemic Allergy
JPS62286923A (en) Enhancer for poor appetite action
FI103258B (en) Process for the preparation of bioactive products derived from two rv
RU2126682C1 (en) Bioactive substance obtained from turf, method of its preparing and pharmaceutical and cosmetic compositions